The chondroprotector mucosat in an integrated approach to the treatment of nonspecific back pain

Fedotova A.V.; Mironova O.P.

doi:https://doi.org/10.17116/jnevro2018118091133

Fedotova A.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Mironova O.P.

The chondroprotector mucosat in an integrated approach to the treatment of nonspecific back pain

Authors:

Fedotova A.V., Mironova O.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(9): 133‑137

DOI: 10.17116/jnevro2018118091133

Read: 4263 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Fedotova AV, Mironova OP. The chondroprotector mucosat in an integrated approach to the treatment of nonspecific back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(9):133‑137. (In Russ.)
https://doi.org/10.17116/jnevro2018118091133

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77

Comparative evaluation of oral chondroprotectors effectiveness in patients with low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):98-103

Musculoskeletal disorders in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):6-10

Ways to optimize the management of lower back pain patients at the outpatient stage. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):148-153

Contemporary concepts of the rational use of centrally acting skeletal muscle relaxants in the treatment of vertebrogenic dorsalgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):154-160

Influence of local anesthesia methods on the results of radiofrequency facet denervation. Burdenko's Journal of Neurosurgery. 2025;(2):57-61

Comparative analysis of the effectiveness of modern physiotherapeutical methods of dorsalgia treatment. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(2):35-44

Abstract:

A nonspecific back pain is in the vast majority of all possible cases of dorsopathies. The sources of back pain may be myogenic dysfunction, intervertebral disc pathology or osteoarthritis of the archicular (facet) joints of the spine, including myofascial pain syndrome. A differentiated approach to the treatment of spondylarthrosis is still an unsolved problem. The article discusses important issues of integration of non-drug treatment methods and drug therapy of nonspecific back pain in patients with facet syndrome. Special attention is paid to SYSADOA group chemicals, in particular chondroitin sulfate (mucosat). These drugs have proven analgesic and anti-inflammatory effects and also are able to improve the structure of the cartilaginous tissue, slowing the progression of the disease.

Keywords:

nonspecific back pain

dorsalgia

osteoarthrosis

spondylarthrosis

facet syndrome

dorsopathies

SYSADOA

chondroprotectors

chondroitin sulfate

mucosat

Authors:

Fedotova A.V.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Mironova O.P.

Close metadata

References:

Jomphe C, Gabriac M, Hale TM, Heroux L, Trudeau LE, Deblois D, Montell E, Verges J, du Souich P. Chondroitin Sulfate Inhibits the Nuclear Translocation of Nuclear factor‐κappaB in Interleukin‐1β — Stimulated Chondrocytes. Basic and Clinical Pharmacology & Toxicology. 2007;102(1):59-65. https://doi.org/10.1111/j.1742-7843.2007.00158.x
Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Practice & Research Clinical Rheumatology. 2010;24(6):769-781. https://doi.org/10.1016/j.berh.2010.10.002
Pergolizzi J, Ahlbeck K, Aldington D, Alon E, Collett B, Coluzzi F, Huygen F, Jaksch W, Kocot-Kepska M, Mangas AC, Margarit C, Mavrocordatos P, Morlion B, Muller-Schwefe G, Nicolaou A. The chronic pain conundrum: should we CHANGE from relying on past history to assessing prognostic factors? Current Medical Research and Opinion. 2012;28(2):249-256. https://doi.org/10.1185/03007995.2011.651525
Schwarzer A, Wang S, Bogduk N, McNaught PJ, Laurent R. Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain. Annals of the Rheumatic Diseases. 1995;54(2):100-106. PMC1005530.
Manchikanti L, Pampati V, Fellows B, Bakhit CE. Prevalence of lumbar facet joint pain in chronic low back pain. Pain Physician. 1999;2(3):59-64. PMID: 16906217.
Kalichman L, Li L, Kim D, Guermazi A, Berkin V, O’Donnell C, Hoffmann U, Cole R, Hunter D. Facet joint osteoarthritis and low back pain in the community-based population. Spine (Phila Pa 1976). 2008;33(23):2560-2565. PMID: 18923337.
Clinical recommendations. Rheumatology. Ed. acad. RAMS E.L. Nasonov. M.: GEOTAR-Media; 2010. (In Russ.)
Nasonova VA, Folomeeva OM, Amirjanova VN, Yakusheva YeO. Analysis of the structure of the XIII class of diseases. Ros Rheumatology. 1998;1:2-7. (In Russ.)
Vorobyova OV. Approaches to treatment of non-recurrent chronic recurrent back pain. Consilium Medicum. 2015;17(2):88-92. (In Russ.) https://con-med.ru/magazines/consilium_medicum/consilium_medicum-02-2015/podkhody_k_terapii_neradikulyarnoy_khronicheskoy_retsidiviruyushchey_boli_v_spine
Campo GM, Avenoso A, Campo S, D’Ascola A, Traina P, Sama D, Calatroni A. Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. Journal of Cellular Biochemistry. 2009;106(1):83-92. https://doi.org/10.1002/jcb.21981
Yackno NN, Kukushkin ML. Pain (a practical guide for doctors). M.: Publishing of Russian Academy of Medical Sciences; 2012. (In Russ)
Yakhno NN, Barinov AN, Podchufarova EV. Neuropathic and musculoskeletal pain. Current approaches to diagnosis and treatment. Klinicheskaya Medicina. 2008;11:9-15. (In Russ)
Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. Journal of Rheumatology. 2000;27(1):205-211. PMID:10648040.
Danilov AB. The antinociceptive effect of chondroprotectors is a myth or a reality? Manage Pain. 2018;1:8-13. (In Russ.) http://logospress.ru/data/med/MP/2018/1-2018/Danilov-1_MP-1-2018.pdf
Monfort J, Nacher M, Montell E, Vila J, Verges J, Benito P. Chondroitin sulfate and Hyaluronic acid (500—730 kDa) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Under Experimental and Clinical Research. 2005;31(2):71-76. PMID: 15929608.
Chou MM, Vergnolle N, McDougall JJ, Wallace JL, Marty S, Teskey V, Buret AG. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1-beta, matrix metalloprotease-9, and cartilage damage in arthritis. Experimental Biology and Medicine (Maywood). 2005;230(4):255-262. PMID: 15792947.
Holzmann J, Brandl N, Zemann A, Schabus R, Marlovits S, Cowburn R, Huettinger M. Assorted effects of TGF-beta and chondroitin sulfate on p38 and ERK1/2 activation levels in human articular chondrocytes stimulated with LPS. Osteoarthritis and Cartilage. 2006;14(6):519-525. PMID: 16503173.
Verbruggen G, Veys EM. Influence of sulphated glycosaminoglycans upon proteoglycan metabolism of the synovial lining cells. Acta Rhumatologica Belgica. 1977;1:75-92. PMID: 755364.
Huang B, Zhuang Y, Li CQ, Liu LT, Zhou Y. Regeneration of the intervertebral disc with nucleus pulposus cell-seeded collagen II/hyaluronan/chondroitin-6-sulfate tri-copolymer constructs in a rabbit disc degeneration model. Spine (Phila Pa 1976). 2011;36(26):2252-2259. PMID: 21358466.
Chan PS, Caron JP, Orth MW. Shot-term gene expression changes in cartilage explants stimulated with interleukin beta glusglucosamine and chondroitin sulfate. Journal of Rheumatology. 2006;33:1329-1340. PMID: 16821268.
Klein RG, Eek BC, O’Neill CW, Mooney V, Derby RR. Biochemical injection treatment for discogenic low back pain: a pilot study. Spine Journal. 2003;3:220-226. PMID: 14589203.
Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Ejik-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMV, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, Mclnnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases. 2017;76(6):960-977. PMID: 28264816.
McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI guidelines for the non surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22:363-388. PMID: 24462672.
Bruyere O, Cooper C, Pelletier JP, Luisa Brandi M, Guillemin F, Hochberg MC, Kanis JA, Kvien TK, Martel-Pelletier J, Rizzoli R, Silverman S, Reginster JY. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism. 2014;44(3):253-263. PMID: 24953861.
An open, uncontrolled study of the efficacy and safety of the parenteral form of chondroitin sulfate (Mucosat). Department of Rheumatology of Leningrad: LENGIDUV; 1990. (In Russ.) https://www.diamed-farma.com/ru/specialists/
Ronca F, Palmieri L, Panicucci P, Ronca G. Antiinflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6:14-21. PMID: 18667340.